These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 15202100)
1. Positron emission imaging of head and neck cancer, including thyroid carcinoma. Schöder H; Yeung HW Semin Nucl Med; 2004 Jul; 34(3):180-97. PubMed ID: 15202100 [TBL] [Abstract][Full Text] [Related]
2. FDG-PET in head and neck, and thyroid cancer. Macapinlac HA Chang Gung Med J; 2005 May; 28(5):284-95. PubMed ID: 16086543 [TBL] [Abstract][Full Text] [Related]
3. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma. Shiga T; Tsukamoto E; Nakada K; Morita K; Kato T; Mabuchi M; Yoshinaga K; Katoh C; Kuge Y; Tamaki N J Nucl Med; 2001 Mar; 42(3):414-9. PubMed ID: 11337516 [TBL] [Abstract][Full Text] [Related]
4. The clinical impact of 18F-FDG gamma PET in patients with recurrent well differentiated thyroid carcinoma. Goshen E; Cohen O; Rotenberg G; Oksman Y; Karasik A; Zwas ST Nucl Med Commun; 2003 Sep; 24(9):959-61. PubMed ID: 12960594 [TBL] [Abstract][Full Text] [Related]
5. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Frilling A; Tecklenborg K; Görges R; Weber F; Clausen M; Broelsch EC Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387 [TBL] [Abstract][Full Text] [Related]
6. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. Kubota K; Yokoyama J; Yamaguchi K; Ono S; Qureshy A; Itoh M; Fukuda H Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):590-5. PubMed ID: 14722678 [TBL] [Abstract][Full Text] [Related]
7. Fluorine-18 fluorodeoxyglucose imaging using dual-head coincidence positron emission tomography without attenuation correction in patients with head and neck cancer. Pai M; Park CH; Suh JH; Koh JH Clin Nucl Med; 1999 Jul; 24(7):495-500. PubMed ID: 10402001 [TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases. Mucha SA; Kunert-Radek J; Pomorski L Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852 [TBL] [Abstract][Full Text] [Related]
9. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer. Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586 [TBL] [Abstract][Full Text] [Related]
10. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma. Wong WL; Chevretton EB; McGurk M; Hussain K; Davis J; Beaney R; Baddeley H; Tierney P; Maisey M Clin Otolaryngol Allied Sci; 1997 Jun; 22(3):209-14. PubMed ID: 9222623 [TBL] [Abstract][Full Text] [Related]
11. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer. Hanasono MM; Kunda LD; Segall GM; Ku GH; Terris DJ Laryngoscope; 1999 Jun; 109(6):880-5. PubMed ID: 10369275 [TBL] [Abstract][Full Text] [Related]
12. PET/CT imaging in recurrent head and neck cancer. Fukui MB; Blodgett TM; Meltzer CC Semin Ultrasound CT MR; 2003 Jun; 24(3):157-63. PubMed ID: 12877412 [TBL] [Abstract][Full Text] [Related]
13. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses. Dennis K; Hay JH; Wilson DC Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464 [TBL] [Abstract][Full Text] [Related]
14. Compare FDG-PET and Tc-99m tetrofosmin SPECT to detect metastatic thyroid carcinoma. Chen YK; Liu FY; Yen RF; Kao CH Acad Radiol; 2003 Aug; 10(8):835-9. PubMed ID: 12945916 [TBL] [Abstract][Full Text] [Related]
15. Use of Diffusion-Weighted Imaging and Noij DP; Martens RM; Koopman T; Hoekstra OS; Comans EFI; Zwezerijnen B; de Bree R; de Graaf P; Castelijns JA Clin Oncol (R Coll Radiol); 2018 Dec; 30(12):780-792. PubMed ID: 30318343 [TBL] [Abstract][Full Text] [Related]
16. Investigation of thyroid, head, and neck cancers with PET. Zhuang H; Kumar R; Mandel S; Alavi A Radiol Clin North Am; 2004 Nov; 42(6):1101-11, viii. PubMed ID: 15488560 [TBL] [Abstract][Full Text] [Related]
17. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma. Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617 [TBL] [Abstract][Full Text] [Related]
18. Detection of neck recurrence in patients with differentiated thyroid cancer: comparison of ultrasound, contrast-enhanced CT and (18)F-FDG PET/CT using surgical pathology as a reference standard: (ultrasound vs. CT vs. (18)F-FDG PET/CT in recurrent thyroid cancer). Seo YL; Yoon DY; Baek S; Ku YJ; Rho YS; Chung EJ; Koh SH Eur Radiol; 2012 Oct; 22(10):2246-54. PubMed ID: 22562091 [TBL] [Abstract][Full Text] [Related]
19. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma. Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422 [TBL] [Abstract][Full Text] [Related]
20. FDG PET in head and neck cancer. Keyes JW; Watson NE; Williams DW; Greven KM; McGuirt WF AJR Am J Roentgenol; 1997 Dec; 169(6):1663-9. PubMed ID: 9393187 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]